Page 458 - fbkCardioDiabetes_2017

434 Cardio Diabetes Medicine 2017

REFERENCES :
1. Stone NJ et al.: 2013 ACC/AHA guideline on the treatment of blood
cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report
of the American College of Cardiology/ American Heart Association task
force on practice guidelines. Circulation 2014, 129(25 Suppl. 2):S1-S45.
2. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin ther-
apy after acute coronary syndromes. N Engl J Med 2015;372: 2387–97
3. Yingzi Chang, Jacques Robidoux. Dyslipidemia management update. Cur-
rent Opinion in Pharmacology 2017; 33:47–55
4. Edward T Carreras, Donna M Polk. Dyslipidemia: Current Therapies And
Guidelines For Treatment. US Cardiology Review 2017;11(1):10–5
5. Allard D, Amsellem S, Abifadel M, et al. Novel mutations of the PCSK9
gene cause variable phenotype of autosomal dominant hypercholesterol-
emia. Hum Mutat 2005; 26:497
6. Ridker PM. SPIRE 1 and SPIRE 2: safety and CV event efficacy of boco-
cizumab in high risk patients. American College of Cardiology Confer-
ence,2017. Washington, DC.

GCDC 2017